Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Melanoma

 

Ipilimumab (Yervoy) 3- vs 10-mg/kg for Metastatic Melanoma
A Randomized Double-Blind Phase III Study of Ipilimumab Administered at 3 mg/kg Versus at 10 mg /kg in Subjects With Previously Treated or Untreated Unresectable or Metastatic Melanoma

Investigator: Kim Margolin, M.D.;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT01515189

Lymph Node Dissection/Observation for Localized Melanoma (7108)
Multicenter Selective Lymphadenectomy for Melanoma Trial II: A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy and Complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node [Randomization phase]

Investigator: David Byrd, MD;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT00389571

Vemurafenib for Metastatic Melanoma Patients With Brain Metastases
An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases

Investigator: Kim Margolin, M.D.;   Conditions: Malignant Melanoma;    Status: Recruiting;   Study ID: NCT01378975

IL-2 "SELECT" for Advanced Melanoma
The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatments in Patients With Advance Melanoma

Investigator: Kim Margolin, MD;   Conditions: Malignant Melanoma;    Status: Recruiting;   Study ID: NCT01288963

Ipilimumab or High-Dose Interferon Alfa-2b for High-Risk Stage III/IV Melanoma
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Investigator: Fred Appelbaum, MD;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT01274338

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer, Colorectal Adenocarcinoma;    Status: Recruiting;   Study ID: NCT00729664

Dose-Escalation Study of MLN4924 (C15005)
A Phase I, Open-Label, Dose Escalation Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients With Melanoma

Investigator: Dr. Shailender Bhatia;   Conditions: Metastatic Melanoma;    Status: Closed/Not Recruiting;   Study ID: NCT01011530

Phase I/II CD8+ NY-ESO-1 (FHCRC 2225)
Phase I/II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cell Clones and Anti-CTLA4 for Patients With Metastatic Melanoma

Investigator: Aude Chapuis, MD;   Conditions: Melanoma (Skin);    Status: Recruiting;   Study ID: NCT00871481

IL-21/Ipilimumab Combination for Melanoma
A Phase I Dose Escalation Study of BMS-982470 (Recombinant Interleukin 21, rIL-21) in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma

Investigator: Shailender Bhatia, M.D.;   Conditions: Melanoma;    Status: Recruiting;   Study ID: NCT01489059